Cargando…

Determining drug dose in the era of targeted therapies: playing it (un)safe?

Targeted therapies against phosphatidylinositol 3-kinase (PI3K), Bruton’s tyrosine kinase (BTK), and B-cell lymphoma-2 (BCL-2) are approved for chronic lymphocytic leukemia (CLL). Since approval of the first-in-class drugs, next-generation agents have become available and are continuously under deve...

Descripción completa

Detalles Bibliográficos
Autores principales: Skånland, Sigrid S., Tjønnfjord, Geir E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9399108/
https://www.ncbi.nlm.nih.gov/pubmed/35999205
http://dx.doi.org/10.1038/s41408-022-00720-7